Under 10% of patients eligible to benefit from weight-loss injections like Wegovy can access them, caution the World Health Organization as it releases its initial guidance on the medications.
With over a billion individuals worldwide currently obese, it is urging broader and more equitable access to GLP-1 medication.
Based on projections, over two billion could be obese by 2030 without intervention.
"The new guidelines affirms that excess weight is a long-term condition that can be treated with thorough and lifelong treatment," stated the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and distribution challenges are major hurdles to universal access to the treatments that can help people shift significant weight, explains the body.
GLP-1 Therapy Shortage
Despite the present most optimistic scenario, the production of GLP-1 therapies might only reach around 100 million people – less than 10% of eligible patients, according to the health organization.
The advice calls on countries and companies to expand access, by strategies like voluntary licensing.
The intellectual property rights on the active ingredient – the main ingredient of a leading brand – is scheduled to end in a number of nations in 2026.
How Obesity Jabs Function
The injections replicate a body's own hormone to reduce digestion speed, suppress the appetite and enhance the sense of being full so people consume fewer calories.
Individuals usually begin shedding pounds after several weeks of commencing the regular doses.
Evidence suggests users may regain a significant portion after a year of stopping the treatment, because their normal food cravings come back.
Being above a healthy weight raises your risk for experiencing medical conditions, like diabetes, heart disease, brain attack, and specific cancers.
Excess weight affects individuals in countries worldwide and was linked to over three and a half million fatalities worldwide in 2024, per the health agency.
